For the Inventor, By the Inventor

Enter assignee name

Wilmington, DE, United States of America

Incyte Holdings Corporation

USPTO Granted Patents = 147

CIPO Patents = 15

EPO Patents = 60

Trademarks = 41

Forward Citations = 2,382

Loading Chart...

Loading Chart...

74 inventors (with patents filed for the assignee):

Yun-Long Li (46 out of 96 patents)

Andrew Paul Combs (46 out of 127 patents)

Wenqing Yao (41 out of 221 patents)

4. James David Rodgers (30 out of 86 patents)

5. Jincong Zhuo (28 out of 76 patents)

6. Chunhong He (27 out of 72 patents)

7. Richard B Sparks (27 out of 63 patents)

8. Eddy W Yue (25 out of 68 patents)

9. Thomas P Maduskuie, Jr (21 out of 51 patents)

10. Song Mei (20 out of 41 patents)

11. Brian Walter Metcalf (17 out of 87 patents)

12. Meizhong Xu (16 out of 39 patents)

13. Wenyu Zhu (15 out of 44 patents)

14. Jiacheng Zhou (15 out of 85 patents)

15. Colin Zhang (15 out of 44 patents)

Core Competencies:

JAK Inhibitors

PI3K Inhibitors

FGFR Inhibitors

BET Protein Inhibitors

Pyrrolo Compounds

Bicyclic Heterocycles

Tricyclic Compounds

Indoleamine 2,3-Dioxygenase

Topical Formulations

Sustained Release Dosage Forms

Imidazopyrimidines

Thiazolecarboxamides

147 patents: Sort by Forward Citations

1. 12427154 - Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same (2025-09-30),

2. 12247030 - Process for preparing compositions comprising an enantiomeric excess of a substituted pyrrolo[2,3-d]pyrimidine (2025-03-11),

3. 12247020 - Bipyrazole derivatives as JAK inhibitors (2025-03-11),

4. 12227502 - 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c] pyridin-7(6H)-ones as inhibitors of BET proteins (2025-02-18),

5. 12226419 - Topical formulation for a JAK inhibitor (2025-02-18),

6. 12201636 - Heterocyclylamines as PI3K inhibitors (2025-01-21),

7. 12152033 - Use of pyrazolopyrimidine derivatives for the treatment of PI3K-δ related disorders (2024-11-26),

8. 12151026 - Sustained release dosage forms for a JAK1 inhibitor (2024-11-26),

9. 12084449 - Imidazotriazines and imidazopyrimidines as kinase inhibitors (2024-09-10),

10. 12024522 - Salts and processes of preparing a PI3K inhibitor (2024-07-02),

11. 11999751 - Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors (2024-06-04),

12. 11905275 - Bipyrazole derivatives as JAK inhibitors (2024-02-20),

13. 11896717 - Sustained-release dosage forms of ruxolitinib (2024-02-13),

14. 11851442 - Tricyclic fused thiophene derivatives as JAK inhibitors (2023-12-26),

15. 11840534 - Substituted tricyclic compounds as FGFR inhibitors (2023-12-12),

Incyte Holdings Corporation is a global biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies. They aim to improve the lives of patients with serious diseases through scientific breakthroughs. With a diverse portfolio of products and a strong pipeline, Incyte is committed to transforming the treatment landscape across a range of therapeutic areas.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

147 Patents

#46 in Wilmington, DE

#60 in Delaware

#2,577 in US

#5,409 in the World

Wilmington, DE, United States of America

Incyte Holdings Corporation

Forward Citations = 2,382

74 inventors:

Yun-Long Li (46 out of 96 patents)

Andrew Paul Combs (46 out of 127 patents)

Wenqing Yao (41 out of 221 patents)

4. James David Rodgers (30 out of 86 patents)

5. Jincong Zhuo (28 out of 76 patents)

Please report any incorrect information to support@idiyas.com

Loading…